Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples